IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v38y2020i5d10.1007_s40273-020-00887-6.html
   My bibliography  Save this article

Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs

Author

Listed:
  • Salah Ghabri

    (French National Authority for Health (Haute Autorité de Santé, HAS))

  • Laurent Lam

    (French National Authority for Health (Haute Autorité de Santé, HAS))

  • François Bocquet

    (CNRS UMR 6297 and University of Paris, Faculty of Pharmacy of Paris, Health and Law Institute, UMR S1145)

  • Hans-Martin Spath

    (University Claude Bernard Lyon 1)

Abstract

Objective This systematic literature review (SLR) had two objectives: to analyse published economic evaluations of biological disease-modifying anti-rheumatic drugs (bDMARDs) for patients with moderate to severe rheumatoid arthritis (RA) previously treated with DMARDs and to assess the quality of those that included sequences of treatments. Methods We performed an SLR on PubMed, Central, Cochrane, and French databases from January 2000 to December 2018. The search focused on cost-effectiveness/utility/benefit analyses. We extracted data on treatment sequences, outcomes (e.g. quality-adjusted life year) and choices of economic evaluation methods (e.g. model type, type of analysis, and method of utility estimation). We analysed the improvement of methods by comparing two sub-periods (2000–2009 and 2010–2018). The quality of reporting and the quality of the methods were assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) and a set of eight key aspects for a reference case for economic evaluation of bDMARDs based on the Outcome Measures in Rheumatology (OMERACT) and Drummond checklists. Data extraction and study assessment were performed independently by two health economists. Results From the 824 records identified in the initial search, 51 publications were selected. Of these, 31 included sequences. Individual models such as discrete-event simulations were used in over two-fifths (22/51, 43%) of the selected studies. Few studies (7/51, 14%) used utility scores based on generic instruments (e.g. EQ-5D). Estimation of hospitalization costs was described in only approximately one-third of studies (19/51). Loss of quality of life (QoL) related to adverse events such as tuberculosis and pneumonia was included in one-tenth (5/51, 10%) of the studies. It was difficult to compare the results of the economic evaluations (i.e. incremental cost-effectiveness ratios) due to the high heterogeneity of studies in terms of disease stage, data sources, inputs, and methods of health outcome assessment used. For identified studies including sequences, the CHEERS assessment of reporting quality showed insufficient reporting of uncertainty analyses and utility weights in more than a third of the studies (11/31, 35%; 9/25, 36%). An in-depth assessment of the quality of the studies revealed that only seven, mostly conducted during the sub-period 2010–2018, addressed the majority of methodological quality assessment issues such as the simulation of patient sequence pathways, the use of systematic reviews and meta-analyses of comparative effectiveness, the choice of treatment sequence, and rules for switching. Conclusion Our SLR identified a lack of high-quality evaluations assessing bDMARD sequences, although some improvements were made in the reporting and modelling of patients’ pathways in studies published after 2010. In order to improve economic evaluations of RA, clear health technology assessment guidance on RA health-related QoL instruments must be provided, and data including long-term disease progression must be made available.

Suggested Citation

  • Salah Ghabri & Laurent Lam & François Bocquet & Hans-Martin Spath, 2020. "Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumati," PharmacoEconomics, Springer, vol. 38(5), pages 459-471, May.
  • Handle: RePEc:spr:pharme:v:38:y:2020:i:5:d:10.1007_s40273-020-00887-6
    DOI: 10.1007/s40273-020-00887-6
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-020-00887-6
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40273-020-00887-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. David Moher & Alessandro Liberati & Jennifer Tetzlaff & Douglas G Altman & The PRISMA Group, 2009. "Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement," PLOS Medicine, Public Library of Science, vol. 6(7), pages 1-6, July.
    2. Drummond, Michael F. & Sculpher, Mark J. & Claxton, Karl & Stoddart, Greg L. & Torrance, George W., 2015. "Methods for the Economic Evaluation of Health Care Programmes," OUP Catalogue, Oxford University Press, edition 4, number 9780199665884.
    3. Alex Diamantopoulos & A. Finckh & T. Huizinga & D. Sungher & L. Sawyer & D. Neto & F. Dejonckheere, 2014. "Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK," PharmacoEconomics, Springer, vol. 32(8), pages 775-787, August.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Antonio Ahumada-Canale & Camila Quirland & Francisco J. Martinez-Mardones & José Cristian Plaza-Plaza & Shalom Benrimoj & Victoria Garcia-Cardenas, 2019. "Economic evaluations of pharmacist-led medication review in outpatients with hypertension, type 2 diabetes mellitus, and dyslipidaemia: a systematic review," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(7), pages 1103-1116, September.
    2. Susanne Mayer & Noemi Kiss & Agata Łaszewska & Judit Simon, 2017. "Costing evidence for health care decision-making in Austria: A systematic review," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-18, August.
    3. Ahmed Ramadan Shokry Shahat & Giulia Greco, 2021. "The Economic Costs of Childhood Disability: A Literature Review," IJERPH, MDPI, vol. 18(7), pages 1-25, March.
    4. Banke-Thomas, Aduragbemi & Aberjirinde, Ibukun-Oluwa & Ayomoh, Francis Ifeanyi & Banke-Thomas, Oluwasola & Eboreime, Ejemai Amaize & Ameh, Charles, 2020. "The cost of maternal health services in low-income and middle-income countries from a provider's perspective: a systematic review," LSE Research Online Documents on Economics 104344, London School of Economics and Political Science, LSE Library.
    5. Devin Incerti & Jeffrey R. Curtis & Jason Shafrin & Darius N. Lakdawalla & Jeroen P. Jansen, 2019. "A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 37(6), pages 829-843, June.
    6. Cochrane, M. & Watson, P.M. & Timpson, H. & Haycox, A. & Collins, B. & Jones, L. & Martin, A. & Graves, L.E.F., 2019. "Systematic review of the methods used in economic evaluations of targeted physical activity and sedentary behaviour interventions," Social Science & Medicine, Elsevier, vol. 232(C), pages 156-167.
    7. Nadia Pillai & Mark Dusheiko & Bernard Burnand & Valérie Pittet, 2017. "A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-22, October.
    8. Darcy M. Anderson & Ryan Cronk & Donald Fejfar & Emily Pak & Michelle Cawley & Jamie Bartram, 2021. "Safe Healthcare Facilities: A Systematic Review on the Costs of Establishing and Maintaining Environmental Health in Facilities in Low- and Middle-Income Countries," IJERPH, MDPI, vol. 18(2), pages 1-22, January.
    9. Nystrand, Camilla & Gebreslassie, Mihretab & Ssegonja, Richard & Feldman, Inna & Sampaio, Filipa, 2021. "A systematic review of economic evaluations of public health interventions targeting alcohol, tobacco, illicit drug use and problematic gambling: Using a case study to assess transferability," Health Policy, Elsevier, vol. 125(1), pages 54-74.
    10. Henriette Busk & Ulrik Sidenius & Line Planck Kongstad & Sus Sola Corazon & Christina Bjørk Petersen & Dorthe Varning Poulsen & Patrik Karlsson Nyed & Ulrika Karlsson Stigsdotter, 2022. "Economic Evaluation of Nature-Based Therapy Interventions—A Scoping Review," Challenges, MDPI, vol. 13(1), pages 1-19, May.
    11. Miriam Kasztura & Aude Richard & Nefti-Eboni Bempong & Dejan Loncar & Antoine Flahault, 2019. "Cost-effectiveness of precision medicine: a scoping review," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 64(9), pages 1261-1271, December.
    12. Zartashia Ghani & Johan Jarl & Johan Sanmartin Berglund & Martin Andersson & Peter Anderberg, 2020. "The Cost-Effectiveness of Mobile Health (mHealth) Interventions for Older Adults: Systematic Review," IJERPH, MDPI, vol. 17(15), pages 1-13, July.
    13. Mina Bahrampour & Joshua Byrnes & Richard Norman & Paul A. Scuffham & Martin Downes, 2020. "Discrete choice experiments to generate utility values for multi-attribute utility instruments: a systematic review of methods," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 983-992, September.
    14. Peter J. Neumann & David D. Kim & Thomas A. Trikalinos & Mark J. Sculpher & Joshua A. Salomon & Lisa A. Prosser & Douglas K. Owens & David O. Meltzer & Karen M. Kuntz & Murray Krahn & David Feeny & An, 2018. "Future Directions for Cost-effectiveness Analyses in Health and Medicine," Medical Decision Making, , vol. 38(7), pages 767-777, October.
    15. Peter Wigfield & Urbano Sbarigia & Mahmoud Hashim & Talitha Vincken & Bart Heeg, 2020. "Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review," PharmacoEconomics - Open, Springer, vol. 4(3), pages 403-418, September.
    16. Valentin Brodszky & Zsuzsanna Beretzky & Petra Baji & Fanni Rencz & Márta Péntek & Alexandru Rotar & Konstantin Tachkov & Susanne Mayer & Judit Simon & Maciej Niewada & Rok Hren & László Gulácsi, 2019. "Cost-of-illness studies in nine Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 155-172, June.
    17. Jason R. Guertin & Blanchard Conombo & Raphaël Langevin & Frédéric Bergeron & Anne Holbrook & Brittany Humphries & Alexis Matteau & Brian J. Potter & Christel Renoux & Jean-Éric Tarride & Madelein, 2020. "A Systematic Review of Methods Used for Confounding Adjustment in Observational Economic Evaluations in Cardiology Conducted between 2013 and 2017," Medical Decision Making, , vol. 40(5), pages 582-595, July.
    18. Henrik Berlin & Martina Vall & Elisabeth Bergenäs & Karin Ridell & Susanne Brogårdh-Roth & Elisabeth Lager & Thomas List & Thomas Davidson & Gunilla Klingberg, 2019. "Effects and cost-effectiveness of postoperative oral analgesics for additional postoperative pain relief in children and adolescents undergoing dental treatment: Health technology assessment including," PLOS ONE, Public Library of Science, vol. 14(12), pages 1-11, December.
    19. Margreet S H Wortman & Joran Lokkerbol & Johannes C van der Wouden & Bart Visser & Henriëtte E van der Horst & Tim C olde Hartman, 2018. "Cost-effectiveness of interventions for medically unexplained symptoms: A systematic review," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-23, October.
    20. Chiranjeev Sanyal & Don Husereau, 2020. "Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 375-392, June.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:38:y:2020:i:5:d:10.1007_s40273-020-00887-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.